{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:51:03Z","timestamp":1764053463335,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.10.002","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T16:20:48Z","timestamp":1476807648000},"page":"273-279.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database"],"prefix":"10.1016","volume":"15","author":[{"given":"Thomas W.","family":"Flaig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi C.","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary B.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneesha","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.10.002_bib1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.10.002_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/imj.12407","article-title":"Prostate cancer: measuring PSA","volume":"44","author":"Pezaro","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.clgc.2016.10.002_bib3","unstructured":"NCCN Guidelines. Prostate cancer, version 1.2015. National Comprehensive Cancer Network web site. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed: March 3, 2016."},{"key":"10.1016\/j.clgc.2016.10.002_bib4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.002_bib5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.002_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/146642400412400518","article-title":"Understanding prostate cancer","volume":"124","author":"Siddiqui","year":"2004","journal-title":"J\u00a0R Soc Promot Health"},{"key":"10.1016\/j.clgc.2016.10.002_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.002_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.10.002_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.10.002_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JOP.2015.004929","article-title":"Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice","volume":"11","author":"Mitchell","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2016.10.002_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.10.002_bib12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2016.10.002_bib13","first-page":"34","article-title":"Age, race, and survival of men with de novo distant metastatic prostate cancer (M1PC)","author":"Bernard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2016.10.002_bib14","first-page":"34","article-title":"Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC)","author":"Alex","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.002_bib15","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2007.13.4536","article-title":"American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer","volume":"25","author":"Basch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.10.002_bib16","first-page":"429","article-title":"Castration-resistant prostate cancer: AUA guideline","volume":"190","author":"Cookson","year":"2013","journal-title":"J\u00a0Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:18Z","timestamp":1761564438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316303111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316303111"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}